Skip to content

Effect of sitagliptin combined with basal insulin therapy during the perioperative period of total joint replacement in patients with non-insulin-dependent type 2 diabetes on blood glucose control: A prospective randomized controlled study

Effect of sitagliptin combined with basal insulin therapy during the perioperative period of total joint replacement in patients with non-insulin-dependent type 2 diabetes on blood glucose control: A prospective randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125916
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

A:Maintain the pre-admission oral hypoglycemic medication regimen (in cases of poor blood sugar control, use regular insulin for emergency treatment)
B:Stop taking oral hypoglycemic drugs and adopt the basal-bolus insulin regimen. The total daily insulin dose is 0.5 U/kg. The basal insulin is half of the total dose, and the remaining half dose is e
C:Stop taking oral hypoglycemic drugs and adopt the sliding scale insulin regimen. The insulin dosage will be adjusted according to the pre-established plan.
D:Stop taking oral hypoglycemic drugs and use 100mg sitagliptin combined with basal insulin therapy (the total daily insulin dose is 0.5U/kg, and the basal insulin is half of the total dose)

Sponsors

Sichuan University, West China Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients who are admitted for the first-time TJA; 2.Blood glucose level is between 140 and 400 mg/dl; 3.Having a diabetes history of more than 3 months; 4.Aged between 18 and 80 years old; 5.Having received only dietary treatment before admission, and have received any oral hypoglycemic drugs or small-dose (daily dose less than 0.4 U/kg) insulin treatment before admission.

Exclusion criteria

Exclusion criteria: 1.No known history of diabetes; 2.Hyperglycemia requiring high-dose (daily dose >= 0.4 U/kg) insulin control for type 2 diabetes; 3.Cardiac surgery; 4.Clinically relevant liver disease or renal dysfunction (serum creatinine 3.0 mg/dL); 5.History of diabetic ketoacidosis and acidosis; 6.Pregnancy; 7.Any mental condition that prevents the subject from giving informed consent.

Design outcomes

Primary

MeasureTime frame
postoperative fasting BG (FBG) ;postprandial BG (PBG) levels;Postoperative insulin resistance level;Hypoglycemia Occurrence frequency;

Secondary

MeasureTime frame
The number and dosage of patients who received insulin as a remedy;Wound complications (hematoma, incision fat liquefaction, superficial incision infection, etc.);Postoperative complications (such as prosthesis loosening, prosthesis-related infection, pneumonia, etc.);

Countries

China

Contacts

Public ContactZongke Zhou

West China Hospital

zhouzongke@scu.edu.cn+86 28 8542 2573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026